Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma-Reference-Cited by-同舟云学术

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Author:

Maruyama Dai¹,Nagai Hirokazu²,Fukuhara Noriko³,Kitano Toshiyuki⁴,Ishikawa Takayuki⁵,Nishikawa Tomoaki⁶

Affiliation:

1. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,

2. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,

3. Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan,

4. Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan,

5. Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan,

6. Janssen Pharmaceutical K.K., Tokyo, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

Reference1 articles.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献